ArticleTropical medicine and health2025
Molecular xenomonitoring highlights post-MDA surveillance priorities for sustained Wuchereria bancrofti elimination in Burkina Faso.
Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study by Nikièma et al. demonstrates the absence of Wuchereria bancrofti infection in Anopheles mosquitoes a decade after cessation of mass drug administration (MDA) in Burkina Faso. This rare longitudinal evidence underscores the utility of molecular xenomonitoring (MX) as a sensitive early-warning tool that complements traditional transmission assessment surveys (TAS). MX enables detection of recrudescence earlier than human-based diagnostics, particularly in low-prevalence settings, and offers opportunities for integration with malaria vector surveillance. Ethical and operational challenges associated with human landing catches highlight the need for alternative trapping methods to maintain MX sensitivity safely. Sustaining lymphatic filariasis elimination globally will depend on institutionalizing MX alongside TAS, ensuring robust surveillance, and safeguarding long-term programmatic gains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.